AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 251 min read$TWST

Laponis Adam sold $273K of TWST

Laponis Adam (Chief Financial Officer) sold 1,965 shares of Twist Bioscience Corp (TWST) at $139.07 ($0.27M total) on 2026-08-21.

Original reporting
SEC EDGAR · Laponis Adam
Published Aug 25, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Insider sale is small; likely limited market reaction.

02

Market read

Minor insider transaction with low trading relevance.

03

What to watch

Possible upcoming corporate actions not disclosed.

Relevance 4/10Novelty 4/10Timing: same-day filing

Background

Form 4 filing by Twist Bioscience CFO indicating a modest share sale.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

CFO Adam Laponis sold 1,965 shares for $273,264, reducing his stake to 108,633 shares.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

Sale amount is small relative to total holdings and market cap; unlikely to move price.

Market effects

Sector

No significant effect on biotech sector.

Regional

None.

Global

Minimal.

Counterpoint

What could challenge this read

Potential undervaluation if insider believes stock is overvalued.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech company specializing in DNA synthesis.

  • Executive
    Adam Laponis

    Chief Financial Officer of Twist Bioscience.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

AUG 23
$MRNAHighAI 9/10

Bond Jitters Meet Biotech Fireworks

Bond market volatility pressured stocks early in the week, with the Nasdaq dropping 2.1%. Biotech stocks surged: Moderna (MRNA) rose 177% after positive cancer trial results, and Twist Bioscience (TWST) gained 23% on AI-driven protein binder success. NVIDIA's earnings and the Jackson Hole symposium are upcoming market tests.

zerohedge.com3 min
AUG 21
$TWSTHighAI 8/10

Twist Bioscience Stock Surges As Anthropic AI Deal And Upbeat Guidance Reset Outlook

Twist Bioscience (TWST) stock rose 6.79% on strong investor optimism. The company reported Q3 revenue of $118.4M, up 23% YoY, with a 78% gross margin but negative EBIT margin and ROE. Guidance was raised to $456M-$457M for FY26, with Q4 adjusted EBITDA breakeven expected. The stock has seen strong technical performance, with resistance near $150 and support at $130-$135.

stockstotrade.com2 min
AUG 19
$TWSTHighAI 8/10

Why is Twist Bioscience stock surging today?

Twist Bioscience (TWST) stock rose 15.3% after Anthropic's research highlighted its role in producing AI-designed proteins. The company filed an 8-K disclosing the collaboration, which supports its AI-driven drug discovery growth narrative. Shares reached a 52-week high of $141.10.

investing.com2 min